Results 31 to 40 of about 1,454 (181)
Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine
Future Pharmacology, 2023 Migraine is ranked as the third most common disorder worldwide and is considered one of the most disabling neurological conditions. Its treatment has mostly relied on medications that were non-specifically developed for migraine, thus accompanied by low ...
Linda Sangalli, Stefania Brazzoli
doaj +1 more source
Medicine in Drug Discovery, 2020 Purpose: Current acute migraine treatment consists of migraine-specific agents, namely triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs and acetaminophen (paracetamol).
David Moreno-Ajona +2 more
doaj +1 more source
Emerging Pharmacological Treatments for Migraine in the Pediatric Population
Life, 2022 Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form.
Luigi Francesco Iannone +2 more
doaj +1 more source
, 2023 Introduction: Migraine is a leading cause of years lived with disability and preventive strategies represent a mainstay to reduce health-related disability and improve quality of life of migraine patients.
Tedeschi, Gioacchino +13 more
core +1 more source
Drugs in Context, 2022 Migraine headaches are widespread, debilitating and considered a main cause of disability worldwide. Symptoms of migraines include unilateral, pulsating pain that can last for hours to days, frequently associated with photophobia and phonophobia, nausea,
Eric R Ocheretyaner +2 more
doaj +1 more source
CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence? [PDF]
Eur J Neurolopen access articleBackground: Medications for migraine prevention targeting the calcitonin gene-related peptide (CGRP) pathway have substantially reduced symptom burden in many patients who have failed previous treatment strategies. In contrast, data on
Tarnutzer AA, Castro Abarca P, Kaski D.
europepmc +2 more sources
, 2023 Supplemental material, sj-pdf-6-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
, 2023 Supplemental material, sj-jpg-3-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
New Approaches to Shifting the Migraine Treatment Paradigm
Frontiers in Pain Research, 2022 The standard of care paradigm for migraine treatment has been based almost exclusively on approaches that grew out of the happenstance use of market pharmaceuticals.
Brian Johnson, Frederick G. Freitag
doaj +1 more source
Future prophylactic treatments in migraine:Beyond anti-CGRP monoclonal antibodies and gepants
, 2021 Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and ...
Do, T. P. +5 more
core +1 more source